Small molecule · developed by Tempest Therapeutics
TPST-1120 is an orally administered agent given twice daily, studied in multiple advanced solid tumors including hepatocellular carcinoma, prostate, renal cell, lung, colorectal, head and neck, breast, urothelial, biliary, gastroesophageal, pancreatic cancers and sarcoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03829436 | Phase 1 | Hepatocellular Carcinoma | Completed | TPST |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CholangiocarcinomaColorectal CancerGastroEsophageal CancerHepatocellular CarcinomaMetastatic Castration Resistant Prostate CancerNon-small Cell Lung CancerPancreatic CancerRenal Cell CarcinomaSarcomaSquamous Cell Carcinoma of Head and NeckTriple-Negative Breast CancerUrothelial Carcinoma
Updated Nov 1, 2026. Something wrong or missing? Report it on the TPST page.
See TPST's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TPST catalysts and pipeline →